Literature DB >> 26711531

Bacteriological resistance in acne: A call to action.

Brigitte Dréno1.   

Abstract

Acne is common in adolescence but is also increasingly seen in adulthood, with about 40% of adults being affected. Topical and systemic oral antibiotics have been used for more than 40 years in the treatment of acne lesions. In the 1970s, evidence of resistance to topical erythromycin and clindamycin was reported and, since then, antibiotic resistance in acne has been increasing worldwide. Antibiotic exposure can be significant in acne treatment because the patient population is large and there is a tendency for prolonged treatment regimens to be prescribed. The overuse of antibiotics is now considered a major public health problem. Action is therefore required to encourage judicial and appropriate use of antibiotics in acne management in line with available evidence-based guidelines. Alternatives to topical antibiotics for the treatment of acne should be considered. Topical antibiotics should no longer be used as monotherapy in acne treatment and use in combination regimens should be limited to a maximum of four weeks. Evidence from studies suggests that, as for topical antibiotics, oral antibiotics should not be used as monotherapy, but instead should be combined with a topical retinoid or benzoyl peroxide for a maximum of four months. Correct and appropriate use of antibiotics in the treatment of acne will help to preserve their utility in the face of increasing antibiotic resistance but greater awareness of the issues is required among prescribing physicians.

Entities:  

Keywords:  P. acnes; acne; acne vulgaris; antibiotic; resistance

Mesh:

Substances:

Year:  2016        PMID: 26711531     DOI: 10.1684/ejd.2015.2685

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  8 in total

1.  A New Topical Candidate in Acne Treatment: Characterization of the Meclozine Hydrochloride as an Anti-Inflammatory Compound from In Vitro to a Preliminary Clinical Study.

Authors:  Philippe A Grange; Guillaume Ollagnier; Laurianne Beauvais Remigereau; Carole Nicco; Constance Mayslich; Anne-Geneviève Marcelin; Vincent Calvez; Nicolas Dupin
Journal:  Biomedicines       Date:  2022-04-19

Review 2.  Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes.

Authors:  Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Maciej Żaczek; Ryszard Międzybrodzki; Sławomir Letkiewicz; Marzanna Łusiak-Szelchowska; Andrzej Górski
Journal:  Front Microbiol       Date:  2017-02-08       Impact factor: 5.640

3.  Challenges and Solutions in Oral Isotretinoin in Acne: Reflections on 35 Years of Experience.

Authors:  Vincenzo Bettoli; Aurora Guerra-Tapia; Maria Isabel Herane; Jaime Piquero-Martín
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-12-30

4.  Tumour Necrosis Factor Alpha-induced Protein 3 Negatively Regulates Cutibacterium acnes-induced Innate Immune Events in Epidermal Keratinocytes.

Authors:  Lilla Erdei; Beáta Szilvia Bolla; Renáta Bozó; Gábor Tax; Edit Urbán; Katalin Burián; Lajos Kemény; Kornélia Szabó
Journal:  Acta Derm Venereol       Date:  2021-01-13       Impact factor: 3.875

Review 5.  New developments in acne treatment: role of combination adapalene-benzoylperoxide.

Authors:  Su Youn Kim; Falk R Ochsendorf
Journal:  Ther Clin Risk Manag       Date:  2016-10-03       Impact factor: 2.423

Review 6.  Optimizing Non-Antibiotic Treatments for Patients with Acne: A Review.

Authors:  Theresa N Canavan; Edward Chen; Boni E Elewski
Journal:  Dermatol Ther (Heidelb)       Date:  2016-08-19

Review 7.  Potential of Curcumin in Skin Disorders.

Authors:  Laura Vollono; Mattia Falconi; Roberta Gaziano; Federico Iacovelli; Emi Dika; Chiara Terracciano; Luca Bianchi; Elena Campione
Journal:  Nutrients       Date:  2019-09-10       Impact factor: 5.717

Review 8.  The Skin Microbiome: A New Actor in Inflammatory Acne.

Authors:  Brigitte Dréno; Marie Ange Dagnelie; Amir Khammari; Stéphane Corvec
Journal:  Am J Clin Dermatol       Date:  2020-09       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.